Veracyte, Inc.
VCYT
Rank in Stocks
#4416
Veracyte, Inc. operates as a diagnostics company in the United States and... Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Share Price
$43.77
Last synced: 2026-10-19
Market Cap
$3.52B
Change (1 day)
1.51%
Change (1 year)
19.43%
Country
US
Trade Veracyte, Inc. (VCYT)
Category
Healthcare
P/B ratio for Veracyte, Inc. (VCYT)
P/B ratio as of October 2026 TTM: 2.50
According to Veracyte, Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 2.50. At the end of 2023 the company had a P/B ratio of 1.91.
P/B ratio history for Veracyte, Inc. from 2011 to 2026
P/B ratio at the end of each year
| Year | P/B Ratio | Change |
|---|---|---|
| 2026 (TTM) | 2.50 | -3.24% |
| 2024 | 2.58 | 34.57% |
| 2023 | 1.91 | 21.21% |
| 2022 | 1.58 | -38.10% |
| 2021 | 2.55 | -58.76% |
| 2020 | 6.19 | 14.98% |
| 2019 | 5.38 | -7.87% |
| 2018 | 5.84 | -1.88% |
| 2017 | 5.95 | 58.90% |
| 2016 | 3.75 | 2.76% |
| 2015 | 3.64 | -27.86% |
| 2014 | 5.05 | 372.94% |
| 2013 | 1.07 | -97.22% |
| 2012 | 38.38 | 74.05% |
| 2011 | 22.05 | 0.00% |
P/B ratio for similar companies or competitors
| Company | P/B Ratio | P/B Ratio Difference | Country |
|---|---|---|---|
| 4.7411 | 89.93% |
US
|
|
| 3.0143 | 20.75% |
US
|
|
| 31.051 | 1,143.88% |
US
|
|
| - | - |
CN
|
|
| 6.6641 | 166.96% |
US
|
